Syndax Pharmaceuticals, Inc. Operating Lease Liability
Syndax Pharmaceuticals, Inc. (SNDX) had Operating Lease Liability of $1.52 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-02-26
- 2025-12-31: Operating Lease, Liability $1.52M.
- 2024-12-31: Operating Lease, Liability $2.05M.
- 2024-10-31: Operating Lease, Liability $1.50M.
- 2023-12-31: Operating Lease, Liability $1.61M.
| Period end | Operating Lease, Liability |
|---|---|
| 2025-12-31 | $1.52M 10-K · filed 2026-02-26 |
| 2024-12-31 | $2.05M 10-K · filed 2025-03-03 |
| 2024-10-31 | $1.50M 10-K · filed 2026-02-26 |
| 2023-12-31 | $1.61M 10-K · filed 2024-02-27 |
| 2022-12-31 | $1.14M 10-K · filed 2023-02-28 |
| 2021-12-31 | $1.07M 10-K · filed 2022-03-01 |
| 2020-12-31 | $417.00K 10-K · filed 2022-03-01 |
| 2019-12-31 | $897.00K 10-K · filed 2021-03-12 |
| 2019-09-30 | $1.00M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $1.25M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $1.40M 10-Q · filed 2019-05-08 |
| 2019-01-01 | $1.30M 10-K · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |